Skip to main content

Table 2 Treatment exposure and tolerance

From: Prognostic and predictive factors for angiosarcoma patients receiving paclitaxel once weekly plus or minus bevacizumab: an ancillary study derived from a randomized clinical trial

 

Arm A (n = 18)

Arm B (n = 24)

p-value

Cycles of paclitaxel: median (range)

6 (2–6)

6 (1–6)

–

Relative dose intensity of paclitaxel: median (range)

0.94 (0.68–1.11)

0.88 (0.55–1.03)

–

Number of bevacizumab injections: median (range)

–

9 (1–39)

–

Related adverse events (Grade ≥ 3): n (%)a

2 (11.1)

10 (41.7)

0.03

  1. aGraded according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us